Abstract
The treatment and prognosis of multiple myeloma have completely changed over the past years with the advent of the new non-chemotherapeutic agents like imids and proteasome inhibitors followed by their second generations and other new drugs. Their side effects are completely different from those seen with standard chemotherapeutic treatment. Some are common, like peripheral neuropathy, blood count changes, venous thromboembolic events, fatigue, and others. These different toxicity profiles allow combinations and sequences of administration, trying to avoid cumulative toxicities and increasing the treatment combinations. In the first edition of this book there were only three but important drugs. Just a few years down the road in this second edition, our armamentarium has enlarged to additional imids and proteasome inhibitors, as well as completely new drugs, being monoclonal antibodies and HDAC inhibitors, and certainly more to come including immuno-oncology drugs. Over the next few years on some of the new drugs, now used in relapsed/refractory myeloma, data will become available also in induction and maintenance therapy. It is highly probable that the explosion of indications of immuno-oncology treatments will include also multiple myeloma. The transformation two decades ago of this lethal disease into a chronic disorder is being further improved and confirmed more and more.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mateos MV. Management of treatment related adverse events in patients with multiple myeloma. Cancer Treat Rev. 2010;36(Suppl 2):S24–32. http://www.ncbi.nim.nih.gov/pubmed/20472185
FDA. US thalidomide label 1–28, NDA 020785, Accessed 5. 2017.
Attal M, Lauwers VC, Marit G, Caillot D, Facon T, Hulin C, et al. Maintenance treatment with lenalidomide after transplantation for myeloma: final analysis of the IMF 2005–02. Blood. 2010;116:310.
McCarthy PL, Owzar K, Anderson KC, Hofmeister CC, Hurd DD, Hassoun H, et al. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation for multiple myeloma: CALGB 100104 abstract. Blood. 2010;116:37.
Stewart AK, Trudel S, Bahlis N, et al. A randomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous stem cell transplantation in patients with multiple myeloma: the NCIC CTG myeloma 10 trial (abstract). Blood. 2010;116(21):39.
Mandala M, Falanga A, Roila F. Management of venous thromboembolism in cancer patients. ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22(Suppl 6):85–92.
Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. Prevention of thalidomide and lenalidomide associated thrombosis in myeloma. Leukemia. 2008;22:414–23.
Delforge M, Bladé J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, et al. Treatment- related peripheral neuropathy in multiple myeloma. The challenge continues. Lancet Oncol. 2010;11:1086–95.
Lipson EJ, Huff CA, Holanda DG, McDevitt MA, Fine DM. Lenalidomide-induced acute interstitial nephritis. Oncologist. 2010;15:961–4.
San Miguel JF, Weisel KC, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055–01066.
Vickrey E, Allen S, Singhal S. Acyclovir to prevent reactivation of varicella-zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer. 2009;115:229–32.
Ludwig H, Adam Z, Hajek R, Greil R, Tóthová E, Keil F, et al. Light chain induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol. 2010;28:4635–41.
Dimopoulos M, Alegre A, Stadtmauer EA, Goldschmidt H, Zonder JA, de Castro CM, et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer. 2010;116:3807–14.
Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754–66.
Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide and dexamethasone for multiple myeloma. NEJM. 2016;375:1319–31.
Lokhorst HM, Plesner T, Lambach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. NEJM. 2016;373:1207–19.
Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621–31.
Richardson PG, Hungria VTM, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood. 2016;127:713–21.
Mateos MV, Orlowski RZ, DiCapua Siegel DS, et al. Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): final efficacy and safety analysis. J Clin Oncol. 2016;34(15_suppl):8010.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Dicato, M.A. (2018). Multiple Myeloma. In: Dicato, M., Van Cutsem, E. (eds) Side Effects of Medical Cancer Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-70253-7_10
Download citation
DOI: https://doi.org/10.1007/978-3-319-70253-7_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-70252-0
Online ISBN: 978-3-319-70253-7
eBook Packages: MedicineMedicine (R0)